Paclitaxel loaded poly(L-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill

被引:72
作者
Liggins, RT
D'Amours, S
Demetrick, JS
Machan, LS
Burt, HM
机构
[1] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada
[2] Angiotech Pharmaceut Inc, Vancouver, BC V6T 1Z4, Canada
[3] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada
[4] Vancouver Hosp & Hlth Sci Ctr, Dept Radiol, Vancouver, BC V6T 2B5, Canada
基金
英国医学研究理事会;
关键词
paclitaxel; microspheres; intraperitoneal administration; carcinomatosis; poly(L-lactic acid);
D O I
10.1016/S0142-9612(00)00080-6
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A controlled release delivery system for paclitaxel was developed using poly(L-lactic acid) to provide local delivery to the peritoneal cavity. Microspheres were made in 1-40 and 30-120 mu m size ranges. In an in vitro release study, 30-120 mu m microspheres loaded with 10, 20 and 30% paclitaxel exhibited a burst phase of release for 3 days followed by an apparently zero-order phase of release. At all loadings, 20-25% of the original load of paclitaxel was released after 30 days. The effect of microsphere size on retention in the peritoneal cavity was assessed. Control 1-40 Crm microspheres were injected intraperitoneally in rats. The rats received either insufflation of the peritoneal cavity using 11 mmHg CO2 or no further treatment. After sacrifice, microspheres with diameters less than 24 mu m were observed in the lymphatic system after being cleared from the peritoneal cavity through fenestrations in the diaphragm. Insufflation of the peritoneal cavity had no effect on the size of microspheres that were cleared. Efficacy studies were carried out using 30-120 mu m microspheres that were of sufficient size to be retained in the peritoneal cavity. In a model of a tumor cell spill after a cecotomy repair, 100 mg of 30-120 mu m microspheres containing 30% paclitaxel were effective in preventing growth of tumors in the peritoneal cavity at both 2 and 6 weeks post-surgery. No gross or histologically evident tumor growth was observed on any peritoneal surfaces or in the surgical wound site. Rats receiving control microspheres all showed tumor cell implantation and growth after 2 weeks. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1959 / 1969
页数:11
相关论文
共 51 条
[1]  
ABERNETHY NJ, 1991, AM J PHYSIOL, V260, P353
[2]  
Abu-Hijleh M. F., 1994, CLIN ANAT, V7, P181, DOI DOI 10.1002/CA.980070403
[3]  
ABUHIJLEH MF, 1995, J ANAT, V186, P453
[4]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[5]   ROLE OF FENESTRATED BASEMENT MEMBRANE IN LYMPHATIC ABSORPTION FROM PERITONEAL CAVITY [J].
ALLEN, L ;
WEATHERFORD, T .
AMERICAN JOURNAL OF PHYSIOLOGY, 1959, 197 (03) :551-554
[6]   The peritoneal stomata [J].
Allen, L .
ANATOMICAL RECORD, 1936, 67 (01) :89-103
[7]  
ARBUCK SG, 1993, SEMIN ONCOL, V20, P31
[8]   PHASE-II TRIAL OF POSTOPERATIVE ADJUVANT INTRAPERITONEAL CISPLATIN AND FLUOROURACIL AND SYSTEMIC FLUOROURACIL CHEMOTHERAPY IN PATIENTS WITH RESECTED GASTRIC-CANCER [J].
ATIQ, OT ;
KELSEN, DP ;
SHIU, MH ;
SALTZ, L ;
TONG, W ;
NIEDZWIECKI, D ;
TROCHANOWSKI, B ;
LIN, SL ;
TOOMASI, F ;
BRENNAN, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :425-433
[9]  
Baker R.W., 1987, CONTROLLED RELEASE B
[10]   CONTROLLED DELIVERY OF TAXOL FROM MICROSPHERES COMPOSED OF A BLEND OF ETHYLENE-VINYL ACETATE COPOLYMER AND POLY (D,L-LACTIC ACID) [J].
BURT, HM ;
JACKSON, JK ;
BAINS, SK ;
LIGGINS, RT ;
OKTABA, AMC ;
ARSENAULT, AL ;
HUNTER, WL .
CANCER LETTERS, 1995, 88 (01) :73-79